Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Oxid Med Cell Longev. 2022 Aug 1;2022:7850659. doi: 10.1155/2022/7850659. eCollection 2022.
Elevated serum low-density lipoproteins (LDL), the substrate for the formation of atherogenic oxidized LDLs (oxLDL), are a causal factor for atherosclerotic cardiovascular disease (ASCVD). Statins are well known to decrease LDL particle concentration and reduce ASCVD morbidity and mortality.
To perform a meta-analysis of the effects of statins (i.e., type, dose, and duration of treatment) on serum levels of oxLDL and on immunoglobulin M (IgM) and immunoglobulin G (IgG) antibody levels against oxLDL.
PubMed, Scopus, Embase, and Web of Science were searched up to February 5th, 2021, for randomized controlled trials (RCT) evaluating the effect of statins on oxLDL and anti-oxLDL antibody levels. Meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V2 software. To evaluate the influence of each study on the overall effect size, a sensitivity analysis was performed using the leave-one-out method. Evaluation of the funnel plot, Begg's rank correlation, and Egger's weighted regression tests was used to assess the presence of publication bias in the meta-analysis.
A total of 28 RCTs including 4019 subjects were finally included in the meta-analysis. The results indicated a significant decrease in circulating concentrations of oxLDL after treatment with statins (SMD: -2.150, 95% CI: -2.640, -1.697, < 0.001). Subgroup analysis found no significant effect of the intensity of statin treatment or statin lipophilicity on the reduction of circulating concentrations of oxLDL. An additional meta-analysis of 3 trials showed that statins did not change the serum levels of IgM and IgG antibodies to oxLDL.
Statin therapy decreases serum oxLDL concentrations but does not affect circulating levels of anti-oxLDL antibodies.
升高的血清低密度脂蛋白（LDL）是形成动脉粥样硬化性氧化 LDL（oxLDL）的底物，是动脉粥样硬化性心血管疾病（ASCVD）的一个致病因素。他汀类药物众所周知可以降低 LDL 颗粒浓度并降低 ASCVD 的发病率和死亡率。
对他汀类药物（即药物类型、剂量和治疗持续时间）对血清 oxLDL 水平以及对 oxLDL 免疫球蛋白 M（IgM）和免疫球蛋白 G（IgG）抗体水平的影响进行荟萃分析。
检索 PubMed、Scopus、Embase 和 Web of Science，截至 2021 年 2 月 5 日，以评估他汀类药物对 oxLDL 和抗 oxLDL 抗体水平影响的随机对照试验（RCT）。使用 Comprehensive Meta-Analysis（CMA）V2 软件进行荟萃分析。为了评估每项研究对总体效应大小的影响，使用了逐一剔除法进行敏感性分析。评估漏斗图、贝格等级相关和埃格加权回归检验，以评估荟萃分析中是否存在发表偏倚。
最终有 28 项 RCT 包括 4019 名受试者被纳入荟萃分析。结果表明，他汀类药物治疗后循环 oxLDL 浓度显著降低（SMD：-2.150，95%CI：-2.640，-1.697， < 0.001）。亚组分析发现他汀类药物治疗强度或亲脂性对降低循环 oxLDL 浓度没有显著影响。对 3 项试验的额外荟萃分析表明，他汀类药物不会改变 oxLDL 抗体的血清 IgM 和 IgG 水平。
他汀类药物治疗可降低血清 oxLDL 浓度，但不影响循环 oxLDL 抗体水平。
Zotero 插件
